IP Verse

Method Of Treating Cancer Using Immune Checkpoint Inhibitor

PatentPatent Analysis

EP3322731

BRISTOL MYERS SQUIBB
Application Number
EP16744626A
Filing Date
Jul 14, 2016
Status
Granted And Under Opposition
Dec 11, 2020
Grant Date
Jan 13, 2021
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3781132B1
EP3818078B1
EP3631454B1

Bibliography

The patent EP3322731B1 was granted to Bristol Myers Squibb on Jan 13, 2021 following the initial filing on Jul 14, 2016 under the application number EP16744626A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions filed by Competitors

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

APPLEYARD LEES FLECK BARBARAOct 13, 2021ADMISSIBLE
GREINEROct 13, 2021ADMISSIBLE
MAIWALDOct 13, 2021ADMISSIBLE
BIONTECHOct 12, 2021ADMISSIBLE
MERCK SHARP & DOHMEOct 12, 2021ADMISSIBLE
PATENT BOUTIQUEOct 12, 2021ADMISSIBLE
KRAUS & LEDERER PARTGMBBOct 7, 2021ADMISSIBLE
REGENERON PHARMACEUTICALSOct 7, 2021ADMISSIBLE
ISA PHARMACEUTICALSOct 6, 2021ADMISSIBLE

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents